Through the 90-day period concluding February 19, 2026, Enliven Therapeutics's top three insider stakeholders include Director Advisors Llc Orbimed (7.66Mn shares), Director Rishi Gupta (7.66Mn shares), Director David P Bonita (1.05Mn shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Advisors Llc Orbimed | 7,663,349 | 20 May, 2024 | |
| Rishi Gupta | 7,663,349 | 20 May, 2024 | |
| David P Bonita | 1,049,767 | 23 Jul, 2021 | |
| Enterprise Associates 14, L.P. New | 652,763 | 07 Apr, 2022 | |
| Mark Chin | 586,018 | 27 Jul, 2021 | |
| Capital Management, L.P. Ra | 530,616 | 27 Feb, 2023 | |
| Braden Michael Leonard | 499,444 | 30 Dec, 2022 | |
| Capital Lp Commodore | 362,160 | 27 Feb, 2023 | |
| Andrew J. Schwab | 240,096 | 27 Feb, 2023 | |
| Samuel Kintz | President And Ceo | 890,392 | 30 May, 2024 |
| Joseph P Lyssikatos | Chief Scientific Officer | 758,938 | 17 Feb, 2026 |
| Partners Vi, Llc 5am | 635,341 | 16 Feb, 2024 | |
| Anish Patel | Chief Operating Officer | 235,011 | 17 Feb, 2026 |
| David M Mott | 57,306 | 23 Feb, 2022 | |
| Richard A. Heyman | 147,550 | 22 Oct, 2024 | |
| Jake Bauer | 21,843 | 27 Feb, 2023 | |
| Benjamin Hohl | Chief Financial Officer | 61,000 | 17 Feb, 2026 |
| Kenneth Attie | Svp And Cmo | 8,525 | 01 Feb, 2022 |
| Lori Anne Kunkel | 30,712 | 19 Dec, 2025 | |
| Michael Gray | Cfo & Coo | 6,903 | 22 Feb, 2023 |
| Helen Louise Collins | Chief Medical Officer | 25,000 | 17 Feb, 2026 |
| Rahul D. Ballal | 22,341 | 10 Oct, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 12 Feb, 2026 | Helen Louise Collins | Common Stock | A | 25,000 | $0.00 | 25,000 | D | A |
| 12 Feb, 2026 | Benjamin Hohl | Common Stock | A | 25,000 | $0.00 | 61,000 | D | A |
| 12 Feb, 2026 | Joseph P Lyssikatos | Common Stock | A | 18,750 | $0.00 | 18,750 | D | A |
| 12 Feb, 2026 | Anish Patel | Common Stock | A | 20,000 | $0.00 | 20,000 | D | A |
| 06 Feb, 2026 | Joseph P Lyssikatos | Common Stock | D | 5,000 | $29.04 | 740,188 | I | S |
| 20 Jan, 2026 | Richard A. Heyman | Common Stock | D | 512 | $26.46 | 24,595 | I | S |
| 20 Jan, 2026 | Richard A. Heyman | Common Stock | D | 718 | $26.96 | 23,877 | I | S |
| 20 Jan, 2026 | Joseph P Lyssikatos | Common Stock | D | 14,509 | $26.90 | 745,188 | I | S |
| 20 Jan, 2026 | Joseph P Lyssikatos | Common Stock | D | 5,491 | $26.37 | 759,697 | I | S |
| 09 Jan, 2026 | Richard A. Heyman | Common Stock | D | 4,285 | $25.00 | 25,107 | I | S |
| 09 Jan, 2026 | Joseph P Lyssikatos | Common Stock | D | 50,000 | $29.13 | 765,188 | I | S |
| 09 Jan, 2026 | Joseph P Lyssikatos | Common Stock | D | 41,198 | $24.90 | 815,188 | I | S |
| 09 Jan, 2026 | Anish Patel | Common Stock | D | 48,057 | $27.98 | 215,254 | I | S |
| 09 Jan, 2026 | Anish Patel | Common Stock | D | 243 | $28.50 | 215,011 | I | S |
| 08 Jan, 2026 | Richard A. Heyman | Common Stock | D | 1,620 | $25.00 | 25,545 | I | S |
| 08 Jan, 2026 | Richard A. Heyman | Common Stock | D | 8,015 | $25.04 | 29,392 | I | S |
| 08 Jan, 2026 | Joseph P Lyssikatos | Common Stock | D | 33,802 | $24.92 | 856,386 | I | S |
| 08 Jan, 2026 | Joseph P Lyssikatos | Common Stock | D | 7,500 | $20.13 | 890,188 | I | S |
| 22 Dec, 2025 | Benjamin Hohl | Common Stock | A | 13,000 | $2.48 | 36,000 | D | M |
| 19 Dec, 2025 | Joseph P Lyssikatos | Common Stock | D | 5,000 | $16.84 | 897,688 | I | S |